Cabergoline: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cabergoline. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Peripheral edema | 1% |
| Impaired concentration | 1% |
| Dependent edema | 1% |
| Pruritus | 1% |
| Constipation | 0% |
| Dyspepsia | 0% |
| Vomiting | 0% |
| Paresthesia | 0% |
| Vertigo | 0% |
| Fatigue | 0% |
| Nervousness | 0% |
| Autonomic nervous system | 0% |
| Breast pain | 0% |
| Dysmenorrhea | 0% |
| Vision abnormal vision | 0% |
| Throat irritation | 0% |
| Toothache | 0% |
| Influenza-like symptoms | 0% |
| Malaise | 0% |
| Acne | 0% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Cabergoline Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.
Source: FDA labeling via NIH DailyMed (set c85d676c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.